Lyra Therapeutics
IPO News: Filed S-1/A: Lyra Therapeutics Launches 3.5mm Share IPO with $14-$16 Marketing Range
Lyra Therapeutics

Lyra Therapeutics

Nasdaq:  LYRA

Initial Filing Date:  03/06/20

Launch Date:  04/27/20

Price Range:  $14.00 - $16.00

Shares Offered (Pre-Shoe | mm):  3.5

Primary Shares (mm):  3.5

Secondary Shares (mm):  0.0

Amount Offered (@ Midpoint)(mm):  $52.5

% Secondary:  0.0%

Shares Outstanding (mm):  12.4

Market Value at Midpoint (mm):  $185.6

Offering as % of Market Value:  28.3%

Bookrunners:  BofA | Jefferies | William Blair

Co-Manager:  BTIG

Major Holders:  Perceptive Advisors | North Bridge Venture Partners | Polaris Venture Partners | RA Capital Management | Intersouth Associates | ArrowMark Partners | Soleus PE

Description:  Lyra is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose and throat, or ENT, diseases.

Note:  Emerging Growth Company

 

Reference Link:  S-1/A